Anti-IgE Treatment

Anti-IgE Treatment

Anti-IgE treatments (like Xolair/Omalizumab) prevent the circulating IgE antibodies from binding to histamine-releasing mast cells. As a result, this helps to reduce the severity of allergic responses.

In the UK, Omalizumab is recommended for use in patients aged 6 years and older who have severe, constant allergic asthma that cannot be controlled with oral or injectable corticosteroids.

Additionally, anti-IgE therapy is approved for the treatment of chronic spontaneous urticaria (chronic hives) in persons aged 12 years and above who do not respond to antihistamines.

How Xolair is Administered

Xolair is given as an injection once or twice a month in a doctor’s office. The dosage is determined based on factors such as the patient’s weight, IgE blood levels and diagnosis.

Key Considerations

Xolair is a long-lasting control medication, which means it is used regularly to prevent asthma symptoms. It is not a fast-relief treatment. While some patients experience rapid improvement, others may gradually see benefits. It is important to note that Xolair may not work for everyone.